Hello, everybody. I'm Sikandar Alabadi from the Mayo Clinic at Jacksonville, Florida. And I'm reaching you from the American study of hematology, the ASH meeting 2025 in Orlando, where I'm talking about a study that presented the at-home administration experience for the first time in a CD38 monoclonal antibody. This one was Isotuximab. This was a subgroup of patients who were treated in the randomized phase three trial called Iroclia. The Iroclia trial had half the patients who got intravenous Isotuximab with pomalidomide and dexamethasone tablets. And the other half got subcutaneous Isotuximab, which is an injection in the skin, but through a device called the on-body injector, an OBI, in combination with pomalidomide and dexamethasone. The original trial, the full study, was what's called non-inferiority, showing that, or it was aiming to show that the on-body injector is not inferior to the standard way of giving it intravenous. And actually that study showed it that the on-body injector was not inferior to get the right amount of drug and the injector worked in nearly 100% cases. But the interesting part about this data that was presented at ASH was a small subset of patients who actually got the drug administered at home. The way the study was set up was that after six cycles of treatment, the patients who were on the on-body injector could actually opt to get the drug at home. It ended up being only a very small number of patients, only 11 patients opted for it and got to that point. And all of those were outside the US in different countries. But what this study nicely showed, this data analysis nicely showed, was that in those patients who got this monoclonal antibody in the convenience of their home, of course it was not self-administered by the patient. A nurse would go to their place and put it on and inject the button. 100% of the times the injector worked. The patients at home did not have any different side effects than patients who got it in the clinic. And the patient experience was very similar whether they got it at home from the drug standpoint. Of course, patients who get it in the convenience of their home may feel positive, but the numbers were so small that a formal analysis could not be done. But I should also say that this on-body injector, which I think it's an amazing new feat in healthcare advancement, the duration of injection, whether the drug was given at home or in the institution, was also very similar. So in a summary, what this data analysis showed was that it is quite feasible to give a monoclonal antibody through this on-body injector to patients in the convenience of their home. Well in a perfect world, I would imagine that hopefully that is the field where our healthcare for myeloma patients can move and they can get a monoclonal antibody in the convenience of their home. And maybe I can even dream of the fact that someday the patients can start self-injecting these immunotherapy drugs to themselves. But that is yet to come, but hopefully we'll get there someday. If our videos have helped you in any way, and you are able to, please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference, and we're deeply grateful for your support.
HealthTree • December 19, 2025